Document:

Exhibit 10.6

 

PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT

 

THIS PRIVATE PLACEMENT WARRANTS PURCHASE
AGREEMENT, effective as of [●], 2020 (as it may from time to time be amended, this “Agreement”), is entered
into by and between Aequi Acquisition Corp., a Delaware corporation (the “Company”), and Aequi Sponsor LLC,
a Delaware limited liability company (the “Purchaser”).

 

WHEREAS:

 

The Company intends to consummate an initial
public offering of the Company’s units (the “Public Offering”), each unit consisting of one share of the
Company’s Class A common stock, par value $0.0001 per share (each, a “Share”), and one-third of one
redeemable warrant as set forth in the Company’s registration statement on Form S-1, filed with the Securities and Exchange
Commission (the “SEC”), File Number 333-249337 (the “Registration Statement”), under the
Securities Act of 1933, as amended (the “Securities Act”);

 

Each whole warrant entitles the holder
to purchase one Share at an exercise price of $11.50 per Share; and

 

The Purchaser has agreed to purchase an
aggregate of 4,000,000 redeemable warrants (or up to 4,400,000 redeemable warrants if the over-allotment option in connection
with the Public Offering is exercised in full) (the “Private Placement Warrants”), each whole Private Placement
Warrant entitling the holder to purchase one Share at an exercise price of $11.50 per Share.

 

NOW THEREFORE, in consideration of the
mutual promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties to this Agreement hereby, intending legally to be bound, agree as follows:

 

AGREEMENT 

 

Section 1. Authorization, Purchase and Sale; Terms of
the Private Placement Warrants. 

 

A. Authorization of the Private Placement
Warrants. The Company has duly authorized the issuance and sale of the Private Placement Warrants to the Purchaser.

 

B. Purchase and Sale of the Private
Placement Warrants.

 

(i) On the date of the consummation of
the Public Offering or on such earlier time and date as may be mutually agreed by the Purchaser and the Company (the “Initial
Closing Date”), the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company,
4,000,000 Private Placement Warrants at a price of $1.50 per warrant for an aggregate purchase price of $6,000,000 (the “Purchase
Price”), which shall be paid by wire transfer of immediately available funds to the Company at least one day prior to
the Initial Closing Date in accordance with the Company’s wiring instructions; provided, however, that the Purchase Price
shall be reimbursed to the Purchaser if the Initial Closing Date does not occur on the day following such wire payment. On the
Initial Closing Date, following the payment by the Purchaser of the Purchase Price by wire transfer of immediately available funds
to the Company, the Company, at its option, shall deliver a certificate evidencing the Private Placement Warrants purchased on
such date duly registered in the Purchaser’s name to the Purchaser, or effect such delivery in book-entry form.

 

(ii) On the date of the consummation of
each closing (if any) of the over-allotment option in connection with the Public Offering or on such earlier time and date as
may be mutually agreed by the Purchaser and the Company (each such date, an “Over-allotment Closing Date”,
and, each Over-allotment Closing Date (if any) together with the Initial Closing Date, being sometimes referred to herein as a
“Closing Date”), the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the
Company, an aggregate of up to 400,000 Private Placement Warrants, in the same proportion as the amount of the over-allotment
option that is then so exercised, at a price of $1.50 per warrant for an aggregate purchase price of up to $600,000 (if the over-allotment
option in connection with the Public Offering is exercised in full) (the “Over-allotment Purchase Price”),
which shall be paid by wire transfer of immediately available funds to the Company at least one day prior to such Over-allotment
Closing Date in accordance with the Company’s wiring instructions; provided, however, that the Over-allotment Purchase Price
shall be reimbursed to the Purchaser if such Over-allotment Closing Date does not occur on the day following such wire payment.
On the Over-allotment Closing Date, following the payment by the Purchaser of the Over-allotment Purchase Price by wire transfer
of immediately available funds to the Company, the Company shall, at its option, deliver a certificate evidencing the Private
Placement Warrants purchased on such date duly registered in the Purchaser’s name to the Purchaser, or effect such delivery
in book-entry form.

 

     

     

    

 

C. Terms of the Private Placement Warrants.

 

(i) Each Private Placement Warrant shall
have the terms set forth in a Warrant Agreement to be entered into by the Company and a warrant agent, in connection with the Public
Offering (the “Warrant Agreement”).

 

(ii) At the time of the closing of the
Public Offering, the Company and the Purchaser shall enter into a registration rights agreement (the “Registration Rights
Agreement”) pursuant to which the Company will grant certain registration rights to the Purchaser relating to the Private
Placement Warrants and the Shares underlying the Private Placement Warrants.

 

Section 2. Representations and Warranties of the Company.
As a material inducement to the Purchaser to enter into this Agreement and purchase the Private Placement Warrants, the Company
hereby represents and warrants to the Purchaser (which representations and warranties shall survive each Closing Date) that:

 

A. Organization and Corporate Power.
The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware and
is qualified to do business in every jurisdiction in which the failure to so qualify would reasonably be expected to have a material
adverse effect on the financial condition, operating results or assets of the Company. The Company possesses all requisite corporate
power and authority necessary to carry out the transactions contemplated by this Agreement and the Warrant Agreement.

 

B. Authorization; No Breach.

 

(i) The execution, delivery and performance
of this Agreement and the Private Placement Warrants have been duly authorized by the Company as of the Closing Date. This Agreement
constitutes the valid and binding obligation of the Company, enforceable in accordance with its terms. Upon issuance in accordance
with, and payment pursuant to, the terms of the Warrant Agreement and this Agreement, the Private Placement Warrants will constitute
valid and binding obligations of the Company, enforceable in accordance with their terms as of each Closing Date.

 

(ii) The execution and delivery by the
Company of this Agreement and the Private Placement Warrants, the issuance and sale of the Private Placement Warrants, the issuance
of the Shares upon exercise of the Private Placement Warrants and the fulfillment of, and compliance with, the respective terms
hereof and thereof by the Company, do not and will not as of each Closing Date (a) conflict with or result in a breach of
the terms, conditions or provisions of, (b) constitute a default under, (c) result in the creation of any lien, security
interest, charge or encumbrance upon the Company’s capital stock or assets under, (d) result in a violation of, or (e) require
any authorization, consent, approval, exemption or other action by or notice or declaration to, or filing with, any court or administrative
or governmental body or agency pursuant to the certificate of incorporation of the Company or the Bylaws of the Company (in effect
on the date hereof or as may be amended prior to completion of the contemplated Public Offering), or any material law, statute,
rule or regulation to which the Company is subject, or any agreement, order, judgment or decree to which the Company is subject,
except for any filings required after the date hereof under federal or state securities laws.

 

C. Title to Securities. Upon issuance
in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement, the Shares issuable upon exercise of the
Private Placement Warrants will be duly and validly issued, fully paid and nonassessable. Upon issuance in accordance with, and
payment pursuant to, the terms hereof and the Warrant Agreement, the Purchaser will have good title to the Private Placement Warrants
and the Shares issuable upon exercise of such Private Placement Warrants, free and clear of all liens, claims and encumbrances
of any kind, other than (i) transfer restrictions hereunder and under the other agreements contemplated hereby, (ii) transfer
restrictions under federal and state securities laws, and (iii) liens, claims or encumbrances imposed due to the actions of
the Purchaser.

 

    	 	2	 

     

    

 

D. Governmental Consents. No permit,
consent, approval or authorization of, or declaration to or filing with, any governmental authority is required in connection with
the execution, delivery and performance by the Company of this Agreement or the consummation by the Company of any other transactions
contemplated hereby.

 

Section 3. Representations and Warranties of the Purchaser.
As a material inducement to the Company to enter into this Agreement and issue and sell the Private Placement Warrants to the Purchaser,
the Purchaser hereby represents and warrants to the Company (which representations and warranties shall survive each Closing Date)
that:

 

A. Organization and Requisite Authority.
The Purchaser possesses all requisite power and authority necessary to carry out the transactions contemplated by this Agreement.

 

B. Authorization; No Breach.

 

(i) This Agreement constitutes a valid
and binding obligation of the Purchaser, enforceable in accordance with its terms, subject to bankruptcy, insolvency, fraudulent
conveyance, reorganization, moratorium and other laws of general applicability relating to or affecting creditors’ rights
and to general equitable principles (whether considered in a proceeding in equity or law).

 

(ii) The execution and delivery by the
Purchaser of this Agreement and the fulfillment of and compliance with the terms hereof by the Purchaser does not and shall not
as of each Closing Date conflict with or result in a breach by the Purchaser of the terms, conditions or provisions of any agreement,
instrument, order, judgment or decree to which the Purchaser is subject.

 

C. Investment Representations.

 

(i) The Purchaser is acquiring the Private
Placement Warrants and, upon exercise of the Private Placement Warrants, the Shares issuable upon such exercise (collectively,
the “Securities”), for the Purchaser’s own account, for investment purposes only and not with a view towards,
or for resale in connection with, any public sale or distribution thereof.

 

(ii) The Purchaser is an “accredited
investor” as such term is defined in Rule 501(a)(3) of Regulation D under the Securities Act.

 

(iii) The Purchaser understands that the
Securities are being offered and will be sold to it in reliance on specific exemptions from the registration requirements of the
United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Purchaser’s
compliance with, the representations and warranties of the Purchaser set forth herein in order to determine the availability of
such exemptions and the eligibility of the Purchaser to acquire such Securities.

 

(iv) The Purchaser did not decide to enter
into this Agreement as a result of any general solicitation or general advertising within the meaning of Rule 502(c) under the
Securities Act.

 

(v) The Purchaser has been furnished with
all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of
the Securities which have been requested by the Purchaser. The Purchaser has been afforded the opportunity to ask questions of
the executive officers and directors of the Company. The Purchaser understands that its investment in the Securities involves a
high degree of risk and it has sought such accounting, legal and tax advice as it has considered necessary to make an informed
investment decision with respect to the acquisition of the Securities.

 

(vi) The Purchaser understands that no
United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or
endorsement of the Securities or the fairness or suitability of the investment in the Securities by the Purchaser nor have such
authorities passed upon or endorsed the merits of the offering of the Securities.

 

(vii) The Purchaser understands that: (a) the
Securities have not been and are not being registered under the Securities Act or any state securities laws, and may not be offered
for sale, sold, assigned or transferred unless (1) subsequently registered thereunder or (2) sold in reliance on an exemption
therefrom; and (b) except as specifically set forth in the Registration Rights Agreement, neither the Company nor any other
person is under any obligation to register the Securities under the Securities Act or any state securities laws or to comply with
the terms and conditions of any exemption thereunder. In this regard, the Purchaser understands that the SEC has taken the position
that promoters or affiliates of a blank check company and their transferees, both before and after a Business Combination, are
deemed to be “underwriters” under the Securities Act when reselling the securities of a blank check company. Based
on that position, Rule 144 adopted pursuant to the Securities Act would not be available for resale transactions of the Securities
despite technical compliance with the requirements of such Rule, and the Securities can be resold only through a registered offering
or in reliance upon another exemption from the registration requirements of the Securities Act.

 

    	 	3	 

     

    

 

(viii) The Purchaser has such knowledge
and experience in financial and business matters, knowledge of the high degree of risk associated with investments in the securities
of companies in the development stage such as the Company, is capable of evaluating the merits and risks of an investment in the
Securities and is able to bear the economic risk of an investment in the Securities in the amount contemplated hereunder for an
indefinite period of time. The Purchaser has adequate means of providing for its current financial needs and contingencies and
will have no current or anticipated future needs for liquidity which would be jeopardized by the investment in the Securities.
The Purchaser can afford a complete loss of its investment in the Securities.

 

(ix) The Purchaser understands that the
Private Placement Warrants shall bear the legend substantially in the form set forth in the Warrant Agreement.

 

Section 4. Conditions of the Purchaser’s Obligations.
The obligations of the Purchaser to purchase and pay for the Private Placement Warrants are subject to the fulfillment, on or before
each Closing Date, of each of the following conditions:

 

A. Representations and Warranties.
The representations and warranties of the Company contained in Section 2 shall be true and correct at and as of such Closing
Date as though then made.

 

B. Performance. The Company shall
have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be
performed or complied with by it on or before such Closing Date.

 

C. No Injunction. No litigation,
statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over
the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement or
the Warrant Agreement.

 

D. Warrant Agreement. The Company
shall have entered into a Warrant Agreement with a warrant agent on terms satisfactory to the Purchaser.

 

Section 5. Conditions of the Company’s Obligations.
The obligations of the Company to the Purchaser under this Agreement are subject to the fulfillment, on or before each Closing
Date, of each of the following conditions:

 

A. Representations and Warranties.
The representations and warranties of the Purchaser contained in Section 3 shall be true and correct at and as of such Closing
Date as though then made.

 

B. Performance. The Purchaser shall
have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be
performed or complied with by the Purchaser on or before such Closing Date.

 

C. No Injunction. No litigation,
statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over
the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement or
the Warrant Agreement.

 

D. Warrant Agreement. The Company
shall have entered into a Warrant Agreement with a warrant agent on terms satisfactory to the Company.

 

Section 6. Termination. This Agreement may be terminated
at any time after [●], 2020 upon the election by either the Company or the Purchaser upon written notice to the other party
if the closing of the Public Offering does not occur prior to such date.

 

Section 7. Survival of Representations and Warranties.
All of the representations and warranties contained herein shall survive each Closing Date.

 

    	 	4	 

     

    

 

Section 8. Definitions. Terms used but not otherwise
defined in this Agreement shall have the meaning assigned to such terms in the Registration Statement.

 

Section 9. Miscellaneous. 

 

A. Successors and Assigns. Except
as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or on behalf of any of the
parties hereto shall bind and inure to the benefit of the respective successors of the parties hereto whether so expressed or not.
Notwithstanding the foregoing or anything to the contrary herein, the parties may not assign this Agreement, other than assignments
by the Purchaser to affiliates thereof.

 

B. Severability. Whenever possible,
each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if
any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective
only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

 

C. Counterparts. This Agreement
may be executed simultaneously in two or more counterparts, none of which need contain the signatures of more than one party, but
all such counterparts taken together shall constitute one and the same agreement.

 

D. Descriptive Headings; Interpretation.
The descriptive headings of this Agreement are inserted for convenience only and do not constitute a substantive part of this Agreement.
The use of the word “including” in this Agreement shall be by way of example rather than by limitation.

 

E. Governing Law. This Agreement
shall be deemed to be a contract made under the laws of the State of New York and for all purposes shall be construed in accordance
with the internal laws of the State of New York.

 

F. Amendments. This Agreement may
not be amended, modified or waived as to any particular provision, except by a written instrument executed by all parties hereto.

 

[Signature page follows]

 

    	 	5	 

     

    

 

IN WITNESS WHEREOF, the parties
hereto have executed this Agreement to be effective as of the date first set forth above.

 

	 	COMPANY:
	 	 
	 	AEQUI ACQUISITION CORP.
	 	 	 
	 	By:	 
	 	 	Name:  	Hope S. Taitz
	 	 	Title: 	Chief Executive Officer
	 	 
	 	PURCHASER:
	 	 
	 	AEQUI SPONSOR LLC
	 	 	 
	 	By:	 
	 	 	Name: 	Hope S. Taitz
	 	 	Title: 	Member

 

6EX-4.1

 Exhibit 4.1 

EXECUTION VERSION 

Supplemental Indenture (this “Supplemental Indenture”), dated as of November 11, 2020, among (i) Wright Medical
Group N.V., a Dutch public limited company (naamloze vennootschNovember 8, 2020ap) (the “Company”); (ii) Wright Luxembourg S.A., a Luxembourg société anonyme (“Wright Luxembourg”) and a
wholly owned subsidiary of the Company; (iii) Wright Medical Ltd., a Bermuda exempted company (“Wright Bermuda”) and a wholly owned subsidiary of Wright Luxembourg; and (iv) The Bank of New York Mellon Trust Company, N.A.,
as trustee (the “Trustee”). 
 W I T N E S S E T H 

WHEREAS, the Company has heretofore executed and delivered to the Trustee an Indenture, dated as of May 20, 2016, providing for the
issuance of the Company’s 2.25% Cash Convertible Senior Notes due 2021 (the “Indenture”); 
 WHEREAS, pursuant to that
certain Purchase Agreement, dated as of November 4, 2019, by and among Stryker Corporation, a Michigan corporation (“Parent”), Stryker B.V., a private company with limited liability (besloten vennootschap met beperkte
aansprakelijkheid) organized under the laws of the Netherlands and direct or indirect wholly owned subsidiary of Parent (“Buyer”), and the Company (the “Purchase Agreement”), Buyer commenced a tender offer (the
“Offer”) for all of the issued and outstanding Ordinary Shares for $30.75 per share, in cash, without interest and less applicable withholding taxes (the “Offer Consideration”), and the Ordinary Shares validly
tendered (and not withdrawn) pursuant to the Offer were accepted for payment by Buyer on November 11, 2020; 
 WHEREAS, pursuant to the
Purchase Agreement, the Company has entered into that certain Agreement and Plan of Merger, dated as of November 10, 2020, by and among Parent, Buyer, the Company, Wright Luxembourg, Wright Bermuda and Stryker Unite, LTD a Bermuda exempted
company (“Merger Sub”) and a wholly owned subsidiary of Buyer (the “Merger Agreement); 
 WHEREAS, pursuant to
the Merger Agreement, the Company, Wright Luxembourg and Wright Bermuda shall effect a series of mergers whereby (i) the Company shall be merged with and into Wright Luxembourg (the “First-Step Merger”), with Wright Luxembourg
being the surviving company of the First Step Merger and each Ordinary Share outstanding immediately prior to the consummation of the First Step Merger being exchanged into one (1) duly authorized, validly issued, fully paid ordinary share, par
value €0.03 per share, of Wright Luxembourg (the “Wright Luxembourg Shares”), (ii) thereafter, Wright Luxembourg shall be merged with and into Wright Bermuda (the “Second Step Merger”), with Wright Bermuda
being the surviving company of the Second Step Merger and each Wright Luxembourg Share outstanding immediately prior to the consummation of the Second Step Merger being converted automatically into one (1) duly authorized, validly issued, fully
paid and non-assessable common share, par value $0.01 per share, of Wright Bermuda (“Wright Bermuda Shares”), and (iii) thereafter, at the Final Effective Time (as such term is defined in
the Merger Agreement), Merger Sub shall be merged with and into Wright Bermuda (the “Third Step Merger” and, together with the First Step Merger and the Second Step Merger, the “Mergers”), with Wright Bermuda being
the surviving company of the Third Step Merger and each Wright Bermuda Share outstanding as of immediately prior to the Final Effective Time being converted automatically into the right to receive the Offer Consideration. 

WHEREAS, pursuant to the Merger Agreement, the Final Effective Time shall occur at 7:30 a.m. New York City Time on November 11, 2020;

 WHEREAS, in connection with the foregoing, Sections 14.07 and 11.01 of the Indenture provides that the Company, Wright Luxembourg, Wright
Bermuda and the Trustee shall execute a supplemental indenture providing that, from and after the Final Effective Time, (i) the Settlement Amount payable upon exchange of the Notes from and after the Final Effective Time shall be calculated
based on 

 
the Offer Consideration that a holder of one Ordinary Share immediately prior to the Mergers would have been entitled to receive upon the occurrence of the Mergers and (ii) Wright Bermuda
shall succeed to and may exercise every right and power of, and expressly assume the obligations of, the Company under the Notes and the Indenture; 

WHEREAS, all conditions necessary to authorize the execution and delivery of this Supplemental Indenture have been complied with or have been
done or performed by the Company; and 
 WHEREAS, the Trustee has received Board Resolutions from the Company and, pursuant to Sections
10.01 of the Indenture, the Trustee is authorized to execute and deliver this Supplemental Indenture. 
 NOW THEREFORE, in consideration of
the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows: 

(1) Capitalized Terms. Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture. 

(2) Assumption. In accordance with Section 11.01 of the Indenture, Wright Bermuda, as the Successor Person from and after the
Final Effective Time, hereby succeeds to and may exercise every right and power of, and assumes any and all obligations of, the Company under the Notes and the Indenture. 

(3) Discharge. Pursuant to Section 11.01 of the Indenture, the Company is hereby discharged from its obligations under the Notes
and the Indenture. 
 (4) Settlement upon Conversion. In accordance with Section 14.07 of the Indenture, from and after the
Final Effective Time, subject to any increase in the Conversion Rate pursuant to, and in accordance with, Sections 14.03 and 14.04 of the Indenture, each $1,000 principal amount of Notes shall be convertible solely into an amount in cash equal to
$30.75 (the “Reference Property”, with each “unit of Reference Property” meaning the kind and amount of Reference Property that a holder of one Ordinary Share is entitled to receive) multiplied by the Conversion
Rate, which is the amount of cash that Holders of the Notes would have been entitled to receive upon the consummation of the Mergers had each $1,000 principal amount of the Notes been converted into a number of Ordinary Shares equal to the
Conversion Rate immediately prior to the Mergers (which amount, for the avoidance of doubt, does not take into account any tax withholding otherwise attributable thereto pursuant to the Merger Agreement). The procedures for settlement upon
conversion set forth in the Indenture shall continue to apply mutatis mutandis to the Holders’ right to convert the Notes into the Reference Property, and any reference in the Indenture to Holders’ right to convert the Notes into
any Settlement Amount shall be deemed to be a reference to Holders’ right to convert the Notes into the Reference Property as set forth in this Supplemental Indenture. 

(5) Other Provisions. Except as expressly provided herein, all other provisions of the Indenture shall remain in full force and effect
and this Supplemental Indenture shall be deemed to be part of the terms and conditions of the Indenture for any all purposes. 
 (6)
Governing Law. THIS SUPPLEMENTAL INDENTURE, AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS SUPPLEMENTAL INDENTURE, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (INCLUDING
TITLE 14 OF ARTICLE 5 OF THE GENERAL OBLIGATIONS LAW OF NEW YORK). 

  
 2 

 (7) Counterparts. The parties may sign any number of copies of this Supplemental
Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. 
 (8) Effect of Headings.
The Section headings herein are for convenience only and shall not affect the construction hereof. 
 (9) The Trustee. The Trustee
shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Company, Wright
Luxembourg and Wright Bermuda. All of the provisions contained in the Indenture in respect of the rights, privileges, protections, immunities, powers and duties of the Trustee shall be applicable in respect of this Supplemental Indenture as fully
and with like force and effect as though fully set forth in full herein. 
 [Signature pages follow.] 

  
 3 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed, all as of the date first above written. 
  

			
	WRIGHT MEDICAL GROUP N.V.
		
	By:	 	/s/ Lance A. Berry
		 	Name: Lance A. Berry
		 	Title:   Executive Vice President, Chief Financial and Operations Officer

  

			
	WRIGHT LUXEMBOURG S.A.
		
	By:	 	/s/ Claire Burningham
		 	Name: Claire Buringham
		 	Title:   Sole Director

  

			
	WRIGHT MEDICAL LTD.
		
	By:	 	/s/ Claire Burningham
		 	Name: Claire Buringham
		 	Title:   Sole Director

 [Signature page – Supplemental Indenture] 

 
			
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee
		
	By:	 	/s/ Valere Boyd
		 	Name: Valere Boyd
		 	Title:   Vice President

 [Signature page – Supplemental Indenture]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]